UBS analyst John Roberts maintains Venator Materials (NYSE:VNTR) with a Neutral and lowers the price target from $3.5 to $2.95.
VYNE Therapeutics Announces BET Inhibitor, VYN201, Demonstrates Improvement In Reducing Fibrotic Tissue Mass And Overall Skin Repair Outcomes In Preclinical Study
VYNE Therapeutics Inc. (NASDAQ:VYNE) (“VYNE” or the “Company”) today announced preclinical data from a validated animal study showing that its bromodomain and extra-terminal (“BET”)
